vTv Therapeutics (NASDAQ:VTVT) Stock Rating Lowered by Wall Street Zen

by · The Markets Daily

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also weighed in on VTVT. Zacks Research raised shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 price target on the stock. Lifesci Capital upgraded shares of vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. Weiss Ratings cut shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, HC Wainwright decreased their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $55.83.

View Our Latest Stock Report on VTVT

vTv Therapeutics Price Performance

NASDAQ VTVT opened at $25.55 on Friday. The stock has a market cap of $100.67 million, a PE ratio of -24.10 and a beta of 0.21. vTv Therapeutics has a fifty-two week low of $19.50 and a fifty-two week high of $44.00. The business has a 50 day moving average price of $30.95 and a two-hundred day moving average price of $32.86.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Sell-side analysts anticipate that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.

Recommended Stories